Difference between revisions of "Tigatuzumab (CS-1008)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) | Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' CS-1008 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | + | [[Category:Intravenous medications]] | |
[[Category:Anti-TRAIL-R2 antibodies]] | [[Category:Anti-TRAIL-R2 antibodies]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
| + | [[Category:Stub]] | ||
Latest revision as of 14:21, 15 April 2021
Mechanism of action
Monoclonal antibody directed against the tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)
Also known as
- Code name: CS-1008